Cargando…

The In Vitro Efficacy of Activated Charcoal in Fecal Ceftriaxone Adsorption among Patients Who Received Intravenous Ceftriaxone

Broad-spectrum antibiotics can kill both pathogens and gut microbiota. Reducing exposure to excess intestinal antibiotics could theoretically protect gut microbiota homeostasis. Recently, engineered charcoals, gel microparticles, and resin beads have demonstrated efficacy in intestinal antibiotic ad...

Descripción completa

Detalles Bibliográficos
Autores principales: Torvorapanit, Pattama, Kawang, Kornthara, Chariyavilaskul, Pajaree, Kerr, Stephen J, Chatsuwan, Tanittha, Nilaratanakul, Voraphoj
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9854876/
https://www.ncbi.nlm.nih.gov/pubmed/36671328
http://dx.doi.org/10.3390/antibiotics12010127
_version_ 1784873236820918272
author Torvorapanit, Pattama
Kawang, Kornthara
Chariyavilaskul, Pajaree
Kerr, Stephen J
Chatsuwan, Tanittha
Nilaratanakul, Voraphoj
author_facet Torvorapanit, Pattama
Kawang, Kornthara
Chariyavilaskul, Pajaree
Kerr, Stephen J
Chatsuwan, Tanittha
Nilaratanakul, Voraphoj
author_sort Torvorapanit, Pattama
collection PubMed
description Broad-spectrum antibiotics can kill both pathogens and gut microbiota. Reducing exposure to excess intestinal antibiotics could theoretically protect gut microbiota homeostasis. Recently, engineered charcoals, gel microparticles, and resin beads have demonstrated efficacy in intestinal antibiotic adsorption in animal studies. We report the first in vitro study evaluating human fecal antibiotic adsorption efficacy of conventional activated charcoal (AC). We collected fecal samples from eight patients who received intravenous (IV) ceftriaxone after admission to King Chulalongkorn Memorial Hospital, Thailand, during January–March 2020. Fecal ceftriaxone was measured by indirect competitive enzyme-linked immunoassays. Three different doses of AC were mixed with fecal samples under a specified protocol. The geometric mean reduction in fecal ceftriaxone concentration when mixed with AC 30 mg/g feces was 0.53 (95% CI 0.33–0.85, p-value < 0.001), meaning 47% adsorption efficacy. Increased adsorption was found with higher doses, 71% and 87% for AC 150 and 500 mg/g feces, respectively. In conclusion, the usual food-poisoning-care dose of conventional AC, 30 mg/g feces, demonstrated dose-dependent and significant fecal ceftriaxone adsorption. Conventional oral AC might be a pragmatic and inexpensive option for the protection of gut microbiota in patients receiving IV ceftriaxone. However, in vivo studies and microbiome analysis are needed for further evidence.
format Online
Article
Text
id pubmed-9854876
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-98548762023-01-21 The In Vitro Efficacy of Activated Charcoal in Fecal Ceftriaxone Adsorption among Patients Who Received Intravenous Ceftriaxone Torvorapanit, Pattama Kawang, Kornthara Chariyavilaskul, Pajaree Kerr, Stephen J Chatsuwan, Tanittha Nilaratanakul, Voraphoj Antibiotics (Basel) Article Broad-spectrum antibiotics can kill both pathogens and gut microbiota. Reducing exposure to excess intestinal antibiotics could theoretically protect gut microbiota homeostasis. Recently, engineered charcoals, gel microparticles, and resin beads have demonstrated efficacy in intestinal antibiotic adsorption in animal studies. We report the first in vitro study evaluating human fecal antibiotic adsorption efficacy of conventional activated charcoal (AC). We collected fecal samples from eight patients who received intravenous (IV) ceftriaxone after admission to King Chulalongkorn Memorial Hospital, Thailand, during January–March 2020. Fecal ceftriaxone was measured by indirect competitive enzyme-linked immunoassays. Three different doses of AC were mixed with fecal samples under a specified protocol. The geometric mean reduction in fecal ceftriaxone concentration when mixed with AC 30 mg/g feces was 0.53 (95% CI 0.33–0.85, p-value < 0.001), meaning 47% adsorption efficacy. Increased adsorption was found with higher doses, 71% and 87% for AC 150 and 500 mg/g feces, respectively. In conclusion, the usual food-poisoning-care dose of conventional AC, 30 mg/g feces, demonstrated dose-dependent and significant fecal ceftriaxone adsorption. Conventional oral AC might be a pragmatic and inexpensive option for the protection of gut microbiota in patients receiving IV ceftriaxone. However, in vivo studies and microbiome analysis are needed for further evidence. MDPI 2023-01-09 /pmc/articles/PMC9854876/ /pubmed/36671328 http://dx.doi.org/10.3390/antibiotics12010127 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Torvorapanit, Pattama
Kawang, Kornthara
Chariyavilaskul, Pajaree
Kerr, Stephen J
Chatsuwan, Tanittha
Nilaratanakul, Voraphoj
The In Vitro Efficacy of Activated Charcoal in Fecal Ceftriaxone Adsorption among Patients Who Received Intravenous Ceftriaxone
title The In Vitro Efficacy of Activated Charcoal in Fecal Ceftriaxone Adsorption among Patients Who Received Intravenous Ceftriaxone
title_full The In Vitro Efficacy of Activated Charcoal in Fecal Ceftriaxone Adsorption among Patients Who Received Intravenous Ceftriaxone
title_fullStr The In Vitro Efficacy of Activated Charcoal in Fecal Ceftriaxone Adsorption among Patients Who Received Intravenous Ceftriaxone
title_full_unstemmed The In Vitro Efficacy of Activated Charcoal in Fecal Ceftriaxone Adsorption among Patients Who Received Intravenous Ceftriaxone
title_short The In Vitro Efficacy of Activated Charcoal in Fecal Ceftriaxone Adsorption among Patients Who Received Intravenous Ceftriaxone
title_sort in vitro efficacy of activated charcoal in fecal ceftriaxone adsorption among patients who received intravenous ceftriaxone
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9854876/
https://www.ncbi.nlm.nih.gov/pubmed/36671328
http://dx.doi.org/10.3390/antibiotics12010127
work_keys_str_mv AT torvorapanitpattama theinvitroefficacyofactivatedcharcoalinfecalceftriaxoneadsorptionamongpatientswhoreceivedintravenousceftriaxone
AT kawangkornthara theinvitroefficacyofactivatedcharcoalinfecalceftriaxoneadsorptionamongpatientswhoreceivedintravenousceftriaxone
AT chariyavilaskulpajaree theinvitroefficacyofactivatedcharcoalinfecalceftriaxoneadsorptionamongpatientswhoreceivedintravenousceftriaxone
AT kerrstephenj theinvitroefficacyofactivatedcharcoalinfecalceftriaxoneadsorptionamongpatientswhoreceivedintravenousceftriaxone
AT chatsuwantanittha theinvitroefficacyofactivatedcharcoalinfecalceftriaxoneadsorptionamongpatientswhoreceivedintravenousceftriaxone
AT nilaratanakulvoraphoj theinvitroefficacyofactivatedcharcoalinfecalceftriaxoneadsorptionamongpatientswhoreceivedintravenousceftriaxone
AT torvorapanitpattama invitroefficacyofactivatedcharcoalinfecalceftriaxoneadsorptionamongpatientswhoreceivedintravenousceftriaxone
AT kawangkornthara invitroefficacyofactivatedcharcoalinfecalceftriaxoneadsorptionamongpatientswhoreceivedintravenousceftriaxone
AT chariyavilaskulpajaree invitroefficacyofactivatedcharcoalinfecalceftriaxoneadsorptionamongpatientswhoreceivedintravenousceftriaxone
AT kerrstephenj invitroefficacyofactivatedcharcoalinfecalceftriaxoneadsorptionamongpatientswhoreceivedintravenousceftriaxone
AT chatsuwantanittha invitroefficacyofactivatedcharcoalinfecalceftriaxoneadsorptionamongpatientswhoreceivedintravenousceftriaxone
AT nilaratanakulvoraphoj invitroefficacyofactivatedcharcoalinfecalceftriaxoneadsorptionamongpatientswhoreceivedintravenousceftriaxone